Allen said...
Clinical stage is never based on biopsy results,
I do not think this is the case. The
American Cancer Society writes:
American Cancer Society said...
"Clinical staging
This is an estimate of the extent of the cancer based on results of physical exams, imaging tests (x-rays, CT scans, etc.), and tumor biopsies".
Also the NCCN guidelines specify on the staging page for T2:
NCCN guidelines said...
*Note: Tumor found in one or both lobes by needle biopsy. (Page ST-1).
So the guidelines refer to needle biopsy for staging.
Further:
NCCN guidelines said...
T2a: Tumor involves one-half of one lobe or less
T2b: Tumor involves more than one half of one lobe but not both lobes
According to the note cited above, T2a und T2b can be determined by needle biopsy.
Allen said...
NCCN does not have any different categories that depend on whether one half of the prostate had positive biopsy cores.
If you take twelve cores as usual, there are six cores for each lobe and half of that is three needles.
The guidelines specify for the low risk category (page pros-2):
NCCN guidelines said...
Fewer than three prostate biopsy cores positive .....
George
Post Edited (George_) : 8/12/2016 11:58:40 AM (GMT-6)